Report

Innate Response Activator B Cells Protect Against Microbial Sepsis

See allHide authors and affiliations

Science  03 Feb 2012:
Vol. 335, Issue 6068, pp. 597-601
DOI: 10.1126/science.1215173

Abstract

Recognition and clearance of a bacterial infection are a fundamental properties of innate immunity. Here, we describe an effector B cell population that protects against microbial sepsis. Innate response activator (IRA) B cells are phenotypically and functionally distinct, develop and diverge from B1a B cells, depend on pattern-recognition receptors, and produce granulocyte-macrophage colony-stimulating factor. Specific deletion of IRA B cell activity impairs bacterial clearance, elicits a cytokine storm, and precipitates septic shock. These observations enrich our understanding of innate immunity, position IRA B cells as gatekeepers of bacterial infection, and identify new treatment avenues for infectious diseases.

Sepsis is characterized by whole-body inflammation in response to overwhelming infection (1). Over the past 30 years, the incidence of sepsis has risen, indicating the need for a better understanding of its complex pathophysiology (2, 3). The growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) elicits multiple changes in cells expressing its cognate receptor. Yet, despite GM-CSF’s multiple functions and known relationship with innate leukocytes, its in vivo cellular source and role in sepsis remain uncertain (4).

Profiling GM-CSF expression by flow cytometry led to a surprising observation. Among the organs, the bone marrow and spleen contained the majority of GM-CSF+ cells in the steady state (1.0 ± 0.1 × 106 and 2.9 ± 0.8 × 105 cells, respectively) (Fig. 1A) (5). In response to lipopolysaccharide (LPS), a component of Gram-negative bacteria, GM-CSF+ cells increased in number preferentially in the spleen (3.2 ± 0.2 × 106 cells) and were predominantly B220+ MHCII+ CD19+ IgM+ B cells (IgM, immunoglobulin M) (Fig. 1B and fig. S1, A and B). This is surprising because GM-CSF is believed to be produced in vivo by nonhematopoietic cells, macrophages, and, in some cases, T cells (4, 6). Nevertheless, B cells constituted the largest GM-CSF+ population under these conditions (fig. S1C), a finding that we confirmed by Western blot analysis (Fig. 1C). We named these B cells innate response activator (IRA) B cells because of GM-CSF’s known role in activating innate leukocytes. Numerous IRA B cells accumulated in the spleen in a mouse model of sepsis (fig. S2, A and B) (7) and in response to Escherichia coli infection (fig. S2C), indicating that IRA B cell expansion is a general feature of the body’s response to bacteria. In humans, we detected CD19+ CD20+ IRA B cells expressing varying levels of CD43, CD27 (fig. S2, D and E), and CD284 [Toll-like receptor 4 (TLR4)] (fig. S2F) (8). We therefore elected to characterize murine IRA B cells in more detail.

Fig. 1

IRA B cells are GM-CSF–producing B cells that increase in number during inflammation. (A) Quantification of GM-CSF–producing cells retrieved from tissues in the steady state and in response to four daily intraperitoneal injections of LPS (means ± SEM, n = 3 to 5 mice). *P < 0.05. (B) Identification of GM-CSF–producing cells in the spleen. Representative plots show percentage of B cells and their production of GM-CSF retrieved from spleens during inflammation. Data represent at least 10 independent experiments. (C) Western blot for GM-CSF conducted on sorted cells. One of three independent experiments is shown. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (D) Colocalization of representative GM-CSF–producing cells with IgM. (E) Red pulp sections with markers against CD11b (green) and GM-CSF (red) (left panel) and B220 (green) and GM-CSF (red) (right panel). Colocalization of green and red cells is shown in yellow. The dashed white curve indicates the border between white and red pulp. (F) Quantification of GM-CSF+ B cells and other cells on histological sections of the spleen in the red pulp and white pulp in the steady state and after LPS (means ± SEM, n = 3 to 4). *P < 0.05. (G) Splenic GM-CSF expression detected by RT-PCR and conducted on sorted cells and on unprocessed spleen tissue taken from WT and B cell knockout (μMT) mice (means ± SEM, n = 3 to 4). *P < 0.05.

Immunofluorescence of spleen sections from LPS recipients colocalized the GM-CSF signal with round mononuclear cells expressing IgM, B220, PAX5, and CD19 (Fig. 1D and fig. S1D) in the red pulp (Fig. 1, E and F). Reverse transcription polymerase chain reaction (RT-PCR) experiments conducted on sorted cells and unprocessed tissue from wild-type (WT) or B cell–deficient μMT mice indicated that B cells produce GM-CSF (Fig. 1G). Serum GM-CSF levels were negligible (that is, below the 7.8 pg/ml detection limit of the assay), a result that is consistent with the observation that GM-CSF is rapidly removed through receptor-mediated clearance (9). Collectively, these data indicate that inflammation expands the IRA B cell population in vivo.

B cells are linked developmentally, reside in different regions, and mediate distinct functions (1014). We profiled IRA B cells according to several well-established methods (13, 15, 16). Our experiments revealed that (CD19+ B220+ MHCII+ GM-CSF+) IRA B cells are phenotypically unique. They are: IgMhigh CD23low CD43high CD93+ (Fig. 2, A and B, and fig. S3A), IgDlow CD21low (fig. S3B), CD138+ VLA4high LFA1high CD284+ (Fig. 2C and fig. S3, C and D), and CD5int (fig. S3, E and F). IRA B cells contain large stores of intracellular IgM (fig. S4A) and spontaneously secrete IgM, but not IgA or IgG1 (fig. S4, B and C). In addition to GM-CSF, IRA B cells produce interleukin-3 (IL-3) but not pro–IL-1β, IL-6, and tumor necrosis factor–α (TNFα) (fig. S4D). We failed to detect IL-10 expression by IRA B cells in any of the conditions. Thus, IRA B cells have a unique B cell phenotype and are functionally distinct from other B cells, including the recently described IL-10–producing B10 B cells (17).

Fig. 2

IRA B cells are a distinct subset with a unique phenotypic signature. (A) Flow cytometric analysis of the phenotype of IRA B cells. Plots show B cell phenotypes retrieved from spleens during steady state and inflammation. A representative from n > 10 mice is shown. (B) Plots show the phenotype of GM-CSF–producing cells in the spleens during inflammation. IRA B cells are IgMhigh, CD23low CD43+ CD93+. (C) Plots show the phenotype of IRA B cells with respect to VLA4 and CD138 expression as determined by flow cytometry. A representative from n > 5 is shown. (D) Hierarchical clustering dendrogram based on whole-genome microarray data of sorted samples of B cell subsets retrieved from LPS-treated animals and steady-state B1a. (E) PCA of the different cell subsets shown in (D).

Sorting IRA B cells according to their surface phenotype (fig. S5A) allowed us to profile their transcriptome. Unsupervised hierarchical clustering (Fig. 2D) and principal component analysis (PCA) (Fig. 2E) grouped IRA B cells in a separate population from T1, FO, MZ, B1a, and PC. IRA B cells also gave rise to a unique transcriptome signature (fig. S5, B to D, and table S1) and expressed genes relevant to B cell biology (fig. S5D).

To decipher where IRA B cells fit in the B cell lineage, we performed several parabiosis and fate-mapping studies. First, we reasoned that if IRA B cells derive from a circulating precursor, they should have high chimerism in a parabiosis setting. Joining CD45.1+ with CD45.2+ mice revealed high chimerism among IRA B cells (Fig. 3A), T1, and FO B cells (fig. S6A) but markedly lower chimerism for the spleen-resident MZ B cells and their precursors (fig. S6A). Thus, IRA B cells derive from a circulating cell.

Fig. 3

IRA B cells develop from B1a B cells via TLR4/MyD88 and reside in tissue through LFA-1/VLA-4. (A) Flow cytometric analysis of the percent chimerism is shown in spleens of CD45.1+ mice that had been in parabiosis with CD45.2+ mice for 3 weeks before LPS injection. Mice were sacrificed 2 days after LPS injection. Representative plots from two independent experiments are shown. (B) Adoptive transfer of peritoneal B1a B cells yields IRA B cells. Cells from steady-state CD45.2+ mice were transferred to CD45.1+ mice that then received LPS for 3 days. Animals were analyzed 72 hours after transfer. Representative plots from flow cytometric analysis of n = 4 to 5 mice are shown. (C) Flow cytometric analysis of the development of IRA B cells in Tlr4–/–, Myd88–/–, Ticam1–/– (the gene that encodes TRIF), μMT, Tnfrsf13c–/– (the gene that encodes BAFFR), and Cd19–/– mice. Representative plots from n = 4 mice are shown. (D) Enumeration of IRA B cells in steady state and inflammation in WT (C57BL/6) mice and in the mice shown in (C) (means ± SEM, n = 4 to 10). *P < 0.05. (E) Flow cytometric analysis of the adoptive transfer of CD45.1+ B1a cells into congenic Tlr4–/– CD45.2+ mice injected with LPS. A representative from n = 3 mice is shown. (F) Flow cytometric analysis of the effect of blocking VLA-4/LFA-1 on IRA B cell retention in the spleen. A representative from n = 3 mice is shown.

Second, to identify the IRA B cell precursor, we adoptively transferred B cell subsets to mice receiving LPS for 3 days (fig. S6, B to E). Among the subsets (splenic T1, FO, MZ, and B1 and peritoneal B1a, B1b, and B2), only peritoneal B1 B cells (Fig. 3B) gave rise to IRA B cells. Of these, B1a B cells were the dominant precursor. B1a-derived IRA B cells readily proliferated (fig. S6E) and developed in the spleen after relocating from the peritoneum (fig. S7). These findings confirm that B1a B cells travel to the spleen in response to peritoneal TLR stimuli (18, 19) and indicate that, upon splenic accumulation, B1a B cells can differentiate to IRA B cells.

The ontogenic relationship between B1a and IRA B cells raised the question of whether IRA B cells constitute a distinct subset. To elucidate this, we first placed peritoneal B1a B cells in culture. In response to LPS, B1a B cells separated into three discrete populations: CD138 cells resembling “unchanged” B1a B cells and two populations of CD138+ cells, one of which was IRA B cells (fig. S8A). In vitro, IRA B cells spontaneously secreted GM-CSF (fig. S8B). We then sorted peritoneal B1a B cells, IRA B cells, and splenic CD43+ CD138+ cells and followed their fate in vivo. B1a B cells gave rise to multiple cell types (fig. S9A), including IRA B and CD43+CD138+ cells, whereas (CD43high CD138+) IRA B and CD43+ CD138+ cells remained phenotypically segregated (fig. S9, B and C). The data suggest that B1a B cells give rise to distinct cells. IRA B cells are a subset of this group.

Surface phenotype and fate-mapping studies, though important, reveal little about function. How IRA B cells arise was our next question. Expectedly, B cell–deficient μMT (20) and Cd19–/– (21) mice did not develop IRA B cells (Fig. 3, C and D). Surprisingly, Tnfrsf13c–/– mice lacking the B cell–activating factor receptor (BAFFR) failed to generate IRA B cells; BAFFR is believed to be dispensable to B1 B cells (22). At the level of microbial recognition, mice lacking the LPS receptor TLR4 or its adaptor MyD88, but not TRIF, did not generate IRA B cells (Fig. 3, C and D), indicating a specific MyD88-dependent pathway. The process could depend on direct B1a binding to LPS via TLR4, or on indirect, extrinsic factors such as TLR4-expressing macrophages. To discriminate between these two possibilities, we adoptively transferred B1a B cells from WT mice into Tlr4–/– mice (Fig. 3E). B1a WT B cells, but not endogenous Tlr4–/– B cells, differentiated to IRA B cells, indicating that direct TLR4 signaling on B1a B cells is sufficient to generate IRA B cells.

To test whether IRA B cells are restricted to TLR4-mediated recognition, we injected TLR ligands Pam3CSK4 (ligand for TLR1/2), Poly(I:C) (TLR3), FLA-ST (TLR5), FSL-1 (TLR2/6), R848 (TLR7/8), and CpG ODN1668 (TLR9). The ligands Pam3CSK4, FSL-1, and R848 yielded IRA B cells (fig. S10A), a finding that we confirmed in vitro (fig. S10B). We also wondered whether GM-CSF can play an autocrine role for B1a–IRA B cell conversion (23). B1a cells expressed Csf2Rβ (CD131) (fig. S11A) and, when placed in culture with antibodies against CD131, failed to give rise to IRA B cells (fig. S11, B and C) but remained alive and gave rise to CD43+ CD138+ cells. Thus, IRA B cells develop via MyD88-dependent pathways and use GM-CSF as an autocrine factor.

The spleen’s open circulation (24) allows blood leukocytes to enter and exit easily. To reside in the spleen, leukocytes resort to adhesive ligands; MZ B cells, for example, rely on VLA-4 and LFA-1 (25). We wondered whether splenic IRA B cells, which express VLA-4 and LFA-1 at high levels, might behave similarly. Injection of neutralizing antibodies to VLA-4 and LFA-1 diminished IRA B cell numbers and revealed that the two integrins are responsible for retention (Fig. 3F).

Are IRA B cells functionally important? To answer this, we focused on the cecal ligation and puncture (CLP) sepsis model (26). We generated mixed chimeras by reconstituting lethally irradiated mice with μMT- and GM-CSF–deficient (Csf2–/–) bone marrow cells. In these mice (called GM/μMT chimeras), the μMT marrow contributed all leukocytes except B cells, whereas the Csf2–/– marrow contributed only Csf2–/– cells. Consequently, the only population completely lacking the capacity to produce GM-CSF in the reconstituted mice were B cells. We tested the quality of the chimeras and their controls by PCR (fig. S11, A and B) and by flow cytometry (fig. S11, C and D).

In response to severe CLP, 40% of control mice survived and recovered, but every GM/μMT chimera died within 2 days (Fig. 4, A and B). To characterize this phenotype further, we profiled GM/μMT chimeras and controls for several sepsis-relevant indices 20 hours after CLP, before any mortalities. Compared with IRA B cell–containing controls (fig. S11E), the peritoneal cavities of GM/μMT chimeras had more leukocytes, mostly neutrophils (Fig. 4C), and experienced a severe IL-1β, IL-6, and TNFα cytokine storm in the serum (Fig. 4D) and peritoneum (Fig. 4E). This inflammatory signature typically associates with a defect in bacterial clearance. Indeed, neutrophils from the GM/μMT chimeras phagocytosed bacteria poorly (Fig. 4F). Moreover, the GM/μMT chimeras had a modest reduction of serum IgM, but not IgG (Fig. 4G), and developed severe liver and lung pathologies (Fig. 4H). Finally, bacterial titer measurements revealed that GM/μMT chimeras were more infected than controls (Fig. 4, I and J). Although it is possible that other bone marrow cells contribute GM-CSF for the protection against sepsis in this setting, the most likely explanation is that IRA B cells protect against septic shock by controlling the organism’s ability to clear bacteria.

Fig. 4

IRA B cells protect against polymicrobial sepsis. (A) Generation of mixed chimeras (GM/μMT). gy, gray; wk, weeks. (B) Kaplan-Meier curve showing survival of GM/μMT and control animals after CLP. n = 10 to 20 mice per group. (C) Enumeration of total leukocytes and neutrophils in the peritoneum of GM/μMT (dark red bars) and control (black bars) mice 20 hours after CLP. ⦰, steady state. *P < 0.05. (D) Serum levels and (E) peritoneal levels of inflammatory cytokines in GM/μMT (dark red) and control (black) mice 20 hours after CLP. (F) Ex vivo phagocytosis assay showing capacity of neutrophils to phagocytose E. coli from GM/μMT (dark red) and control (black) mice 20 hours after CLP. (G) Serum levels of IgM and IgG 20 hours after CLP in the same groups as above. (H) Representative hematoxylin and eosin stain of liver and lung sections 20 hours after CLP in the same groups as above. (I) Blood from GM/μMT and control mice 20 hours after CLP was plated for 1 day. Representative plate shows bacterial colonies. (J) Enumeration of bacteremia in the peritoneum and blood of GM/μMT (dark red) and control (black) mice 20 hours after CLP. *P < 0.05 [means ± SEM, n = 10 to 20 mice per group for (C) to (G) and (J). Four independent experiments were performed and data were grouped].

GM-CSF is a pleiotropic cytokine that influences the production, maturation, function, and survival of its target cells. GM-CSF’s role in sepsis has remained elusive because its indiscriminate ablation is protective (27), but its supplementation can be beneficial (28). The in vivo identification of GM-CSF–producing B cells illustrates a previously unrecognized locational specificity that dictates the cytokine’s function. IRA B cells differ from other subsets because their pathogen recognition pathways and tissue distribution license GM-CSF expression. The function is important in sepsis and gives rise to questions as to how IRA B cells participate in other infectious and inflammatory diseases.

Supporting Online Material

www.sciencemag.org/cgi/content/full/science.1215173/DC1

Materials and Methods

Figs. S1 to S12

Table S1

References (2936)

References and Notes

  1. Materials and methods are available as supporting material on Science Online.
  2. Acknowledgments: This work was supported in part by NIH grants 1R01HL095612 (to F.K.S.), as well as U01 HL080731, P50 CA86355, R24 CA69246, and P01-A154904 (to R.W.). P.J.R. was supported by the Boehringer Ingelheim Fonds; C.S.R. was supported by an American Heart Association postdoctoral fellowship and the MGH Executive Committee on Research (ECOR) Postdoctoral Award; G.F.W. and I.H. were supported by the German Research Foundation; and I.T. was supported by the Max Kade Foundation. We thank K. Rajewsky, D. Scadden, A. Luster, and K. Otipoby (Harvard Medical School) for helpful discussions and critical reading of the manuscript and M. Greene for secretarial assistance. The data reported in this paper are tabulated in the main paper and in the supporting online material. MIAME (minimum information about a microarray experiment)–compliant expression data have been deposited under the accession no. GSE32372.
View Abstract

Navigate This Article